IUDs, implants, Depo-Provera have "incredible return on investment".
D000569:Americas; D003267:Contraception; D003270:Contraceptive Agents; D003271:Contraceptive Agents, Female; D003362:Cost-Benefit Analysis; D003710:Demography; D019049:Developed Countries; D004467:Economics; D005069:Evaluation Studies as Topic; D005193:Family Planning Services; D005298:Fertility; D005376:Financial Management; D007348:Insurance, Health; D007434:Intrauterine Devices; D016912:Levonorgestrel; D017258:Medroxyprogesterone Acetate; D009656:North America; D011153:Population; D011157:Population Dynamics; D011247:Pregnancy; D012106:Research; D012725:Sexual Behavior; D014481:United States
D003270:Contraceptive Agents; D003271:Contraceptive Agents, Female; D016912:Levonorgestrel; D017258:Medroxyprogesterone Acetate
Americas; Comparative Studies; Contraception; Contraceptive Agents; Contraceptive Agents, Female; Contraceptive Agents, Progestin; Contraceptive Implants; Contraceptive Methods--cost; Cost Effectiveness; Demographic Factors; Depo-provera; Developed Countries; Economic Factors; Evaluation; Evaluation Indexes; Family Planning; Fertility; Financial Activities; Health Insurance; Iud; Levonorgestrel; Medroxyprogesterone Acetate; North America; Northern America; Population; Population Dynamics; Pregnancy, Unplanned--cost; Quantitative Evaluation; Reproductive Behavior; Research Methodology; Studies; United States